Semaglutide is the name most people search for in metabolic peptide research — it's the compound that made the incretin field famous. But it's the first of three generations researchers now compare, and the newer two engage more receptors. If you've been trying to understand how Semaglutide, Tirzepatide and Retatrutide actually differ, here's the plain-English version.
The quick answer
The simplest way to hold the three apart is by how many receptors each one engages:
- Semaglutide — a single receptor agonist (GLP-1 only). The original, most-studied reference compound.
- Tirzepatide — a dual receptor agonist (GLP-1 + GIP).
- Retatrutide — a triple receptor agonist (GLP-1 + GIP + glucagon).
Each generation added a receptor to the one before it. That progression — single, dual, triple — is the whole story in a sentence.
What the receptors do
All three act on the incretin system, the body's network for glucose regulation and appetite signalling. The differences come down to which receptors each compound reaches:
- GLP-1 receptor — the foundational incretin target, central to glucose-regulation and appetite-signalling research. All three compounds act here.
- GIP receptor — the second incretin target, studied for its complementary role alongside GLP-1. Tirzepatide and Retatrutide add this one; Semaglutide does not.
- Glucagon receptor — involved in energy expenditure and mobilising stored energy. Only Retatrutide reaches this third receptor.
For a deeper look at these three pathways and how single, dual and triple agonists sit within them, see our GLP-1, GIP & glucagon research landscape guide.
Side-by-side
- Semaglutide: GLP-1 only (single agonist) — the established first-generation reference compound.
- Tirzepatide: GLP-1 + GIP (dual agonist) — the dual-incretin step that followed.
- Retatrutide: GLP-1 + GIP + glucagon (triple agonist) — the newest frontier, adding the glucagon pathway.
- Research areas: all three appear across glucose-regulation, appetite-signalling and body-composition research.
- Handling: all are lyophilised powders — store at −20°C, reconstitute with bacteriostatic water, and refrigerate once mixed.
How the field progressed
The three compounds represent a clear line of development. Semaglutide established what a single-receptor GLP-1 agonist could do and became the benchmark everything else is measured against. Tirzepatide asked what adding the GIP receptor would contribute, making it the reference dual agonist. Retatrutide then added the glucagon receptor to explore energy-expenditure pathways the first two don't touch. Newer doesn't mean "better" — it means "engages more pathways," which is only an advantage if a study is actually designed to examine those pathways.
Which one for a research protocol?
There's no universal winner — the right compound is the one that matches the question being asked. A protocol examining single-receptor GLP-1 mechanisms references Semaglutide. One built around the dual-incretin mechanism references Tirzepatide. One investigating the added glucagon pathway references Retatrutide. Researchers choose the tool that fits the mechanism they're studying, not the one that hits the most receptors. If you're weighing the two newer compounds specifically, our Retatrutide vs Tirzepatide breakdown goes deeper on that pair.
Sourcing in Australia
We hold both Tirzepatide and Retatrutide in Australian stock — independently batch-tested with published Certificates of Analysis, dispatched same or next business day from Melbourne. With high-value metabolic peptides, verified purity and identity are what separate a usable research tool from an unknown; you can see the actual lab results for each batch in our CoA Library before you order.
Shop metabolic research peptides
All products are supplied strictly for laboratory and in-vitro research use only. Not for human or veterinary consumption. This article describes fields of scientific research and is not medical advice or a claim about effects in humans.